EP3551629
Oxabísýklóheptan til stillingar á ónæmissvörun
:
EP einkaleyfi í gildi á Íslandi:
8.12.2017:
15.11.2023:
17879038.2
:
5.2.2024:
15.3.2024
:
7.12.2037:
7.12.2025:
31.12.2025
:
OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE
8.12.2017
15.11.2023
5.2.2024
15.3.2024
7.12.2025
:
Lixte Biotechnology, Inc.:
680 E. Colorado Blvd., Suite 180, Pasadena, CA 91101, US
:
The U.S.A. as represented by the Secretary, Department of Health and Human Services:
Office of Technology Transfer National Institutes of Health, 6701 Rockledge Drive, Suite 700, Bethesda, MD 20892, US
:
KOVACH, John S.:
East Setauket, New York 11733, US
:
ZHUANG, Zhengping:
Bethesda, Maryland 20814, US
:
HO, Sze Chun Winson:
6011 Executive Boulevard Suite 325, MSC 7660 Bethesda, Maryland 20892-7660, US
:
WANG, Herui:
6011 Executive Boulevard Suite 325, MSC 7660 Bethesda, Maryland 20892-7660, US
:
LU, Rongze:
Sunnyvale, CA 94085, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201662497949 P:
8.12.2016:
US
:
201762465001 P:
28.2.2017:
US
:
201762545373 P:
14.8.2017:
US
:
US2017065270:
8.12.2017
:
C07D 471/04, C07D 405/14, A61K 31/4439, A61K 9/00, A61K 31/4525, A61K 39/395, A61K 45/06, A61P 35/00, C07K 16/28, A61K 39/00
: 7
: 31.1.2024
: 7.12.2024
: Árnason Faktor ehf.
: 8
: 10.12.2024
: 7.12.2025
: G.H. Sigurgeirsson ehf.